A double-blind, randomized, two-part, two-period crossover study to evaluate the pharmacokinetics of caffeine versus d9-caffeine in healthy subjects

Deura9™ (d9-Caffeine) demonstrated higher exposure levels and significantly fewer unwanted metabolites with a smoother bioavailability profile, avoiding the "caffeine crash"

Researchers